Epstein–Barr virus-positive diffuse large B-cell lymphoma following acute myeloid leukemia: a common clonal origin indicated by chromosomal translocation t(3;4)(p25;q21)

Higuchi, Masakazu; Sasaki, Satoshi; Kawadoko, Shin ichiro; Uchiyama, Hikaru; Yasui, Takaharu; Kamihira, Takashi; Aoki, Ken; Sasaguri, Toshiyuki; Nakano, Ryuichi; Uchiyama, Akihiko; Muta, Tsuyoshi; Ohshima, Koichi

doi:10.1007/s12185-015-1802-4

Cited by 5 publications

(4 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There have been several reports on malignant lymphoma arising as a second malignancy in patients with hematological malignancies (3-5); however, malignant lymphoma arising from MDS following treatment with AZA is rare. EBV-positive DLBCL that is not related to HIV was almost classified among the “other iatrogenic immunodeficiency-associated lymhoproliferative disorders” or as “EBV-positive diffuse large B-cell lymphoma of the elderly” in the WHO 2008 criteria.…”

Section: Discussionmentioning

confidence: 99%

EBV-positive Diffuse Large B-cell Lymphoma as a Secondary Malignancy Arising in a Myelodysplastic Syndrome Patient who Was Treated with Azacitidine

et al. 2017

View full text Add to dashboard Cite

We report a case of secondary diffuse large B-cell lymphoma (DLBCL) after azacitidine (AZA) treatment in a 63-years-old man with myelodysplastic syndrome. The patient suffered from febrile neutropenia after 10 cycles of AZA treatment. Despite the performance of a whole-body CT scan, which showed a multifocal low-density area in the liver and a multifocal nodular shadow in the lung, no malignant neoplasms could be detected. An autopsy was performed 6 months later, and a histopathological examination of the lesions of the liver and lung revealed the infiltration of large round-shaped tumor cells with necrotizing lesions. Immunohistochemically, the tumor cells were positive for CD20 and EBER, indicating EBV-positive DLBCL as a secondary malignancy.

show abstract

Section: Discussionmentioning

confidence: 99%

EBV-positive Diffuse Large B-cell Lymphoma as a Secondary Malignancy Arising in a Myelodysplastic Syndrome Patient who Was Treated with Azacitidine

et al. 2017

View full text Add to dashboard Cite

show abstract

“…However, secondary lymphoid tumors following AML are rare. Higuchi, et al reported Epstein-Barr virus-positive DLBCL during CR of AML [15]. In this case, the rearrangement patterns of the IGH in the two malignancies were different.…”

Section: Discussionmentioning

confidence: 69%

Diffuse Large B-Cell Lymphoma during Complete Remission of Acute Myeloid Leukemia (M4Eo) Exhibiting Immunoglobulin Heavy Chain Gene Rearrangement and Inv(16)

Kuriyama¹,

Hosoi²,

Masaya³

et al. 2019

Int J Blood Res Disord

View full text Add to dashboard Cite

Background: In previous studies, it has been reported that 10-20% of acute myeloid leukemia (AML) cases showed immunoglobulin heavy chain gene (IGH) rearrangements, a genetic hallmark of B-cell differentiation. However, the clinical significance of this is uncertain. Here, we report a case of diffuse large B-cell lymphoma (DLBCL) after complete remission (CR) from AML that exhibited an IGH rearrangement. Case presentation: The patient was diagnosed with AML (M4Eo) with inversion of chromosome 16 [inv(16)]. Interestingly, the AML cells showed a monoallelic IGH rearrangement, as detected by the Southern blot analysis. The rearranged band was cloned using the inverse polymerase chain reaction (PCR) method. The sequence result revealed that a recombination between DH7-27 and JH4 occurred in the AML cells. PCR using DH7-27and JH4-specific primers yielded no band from DLBCL specimens, suggesting that the DLBCL did not occur owing to the AML cell with IGH rearrangement. In addition, fluorescent in situ hybridization (FISH) showed that inv(16) was not found in the DLBCL cells. Therefore, although the AML cells harbored an IGH rearrangement, the origins of the two tumors seemed to differ from each other. Conclusion: As the prognosis of AML became better, longterm follow-up studies of AML patients might define the clinical significance of IGH rearrangements in AML cells.

show abstract

“…Diffuse large B-cell lymphoma (DLBCL) and acute myeloid leukemia (AML) rarely occur concurrently. Only a few cases of DLBCL after AML chemotherapy[ 1 , 2 ] have been reported. Chemotherapy-induced immunosuppression predisposes patients to develop secondary malignancies, particularly virus-related ones[ 1 , 2 ].…”

Section: Introductionmentioning

confidence: 99%

“…Only a few cases of DLBCL after AML chemotherapy[ 1 , 2 ] have been reported. Chemotherapy-induced immunosuppression predisposes patients to develop secondary malignancies, particularly virus-related ones[ 1 , 2 ]. Only two cases with a synchronous diagnoses of DLBCL and AML have been reported[ 3 , 4 ].…”

Section: Introductionmentioning

confidence: 99%

Coexistence of diffuse large B-cell lymphoma, acute myeloid leukemia, and untreated lymphoplasmacytic lymphoma/waldenström macroglobulinemia in a same patient: A case report

Liu-bo¹,

Lu²,

Xin³

et al. 2023

World J Clin Cases

View full text Add to dashboard Cite

BACKGROUND The Coexistence of myeloid and lymphoid malignancies is rare. Myeloid leukemia occurs more frequently as a secondary event in patients receiving chemotherapy agents for lymphoid malignancies. Synchronous diagnoses of diffuse large B-cell lymphoma (DLBCL), acute myeloid leukemia (AML), and untreated lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (LPL/WM) in the same patient have not been reported. Here we report one such case. CASE SUMMARY An 89-year-old man had a chest wall mass histopathologically diagnosed as DLBCL. The bone marrow and peripheral blood contained two groups of cells. One group of cells fulfilled the criteria of AML, and the other revealed the features of small B lymphocytic proliferative disorder, which we considered LPL/WM. Multiple chromosomal or genetic changes were detected in bone marrow mononuclear cells, including ATM deletion, CCND1 amplification, mutations of MYD88 (L265P) and TP53 , WT1 overexpression, and fusion gene of BIRC2-ARAP1 , as well as complex chromosomal abnormalities. The patient refused chemotherapy because of old age and died of pneumonia 1 mo after the final diagnosis. CONCLUSION The coexistence of DLBCL, AML, and untreated LPL/WM in the same patient is extremely rare, which probably results from multiple steps of genetic abnormalities. Asymptomatic LPL/WM might have occurred first, then myelodysplastic syndrome-related AML developed, and finally aggressive DLBCL arose. Therefore, medical staff should pay attention to this rare phenomenon to avoid misdiagnoses.

show abstract

Epstein–Barr virus-positive diffuse large B-cell lymphoma following acute myeloid leukemia: a common clonal origin indicated by chromosomal translocation t(3;4)(p25;q21)

Cited by 5 publications

References 26 publications

EBV-positive Diffuse Large B-cell Lymphoma as a Secondary Malignancy Arising in a Myelodysplastic Syndrome Patient who Was Treated with Azacitidine

EBV-positive Diffuse Large B-cell Lymphoma as a Secondary Malignancy Arising in a Myelodysplastic Syndrome Patient who Was Treated with Azacitidine

Diffuse Large B-Cell Lymphoma during Complete Remission of Acute Myeloid Leukemia (M4Eo) Exhibiting Immunoglobulin Heavy Chain Gene Rearrangement and Inv(16)

Coexistence of diffuse large B-cell lymphoma, acute myeloid leukemia, and untreated lymphoplasmacytic lymphoma/waldenström macroglobulinemia in a same patient: A case report

Contact Info

Product

Resources

About